Asia-Pacific type 2 diabetes market to hit $10.5 billion by 2020

6 January 2015

The type 2 diabetes treatment market in Asia-Pacific (APAC) region will rise in value from an estimated $6.5 billion in 2013 to $10.5 billion by 2020, representing a modest compound annual growth rate (CAGR) of 7.1%.

According to business intelligence provider GBI Research latest report, of the four major APAC countries (China, India, Japan and Australia), China will see the fastest expansion, with a CAGR of 11.1% over the forecast period. This will be driven by an increase in the prevalent population due to urbanization, and by expected drug launches.

Arti Singh, an analyst for GBI Research, says: “The increasing diabetic population in India and China is the major reason behind the diabetes treatment market growth in the APAC region as a whole. While metformin is expected to retain its dominant position in the treatment algorithm for type 2 diabetes, the anticipated launch of promising pipeline molecules, including several drugs with novel mechanisms of action, may also contribute to market expansion.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical